Actually it is “OOri”, a drone, developed by the company UVify, which is a San Francisco based company having a strong passion of developing drones.
OOri is a “Fun. Fast. Smart” drone as it can easily be controlled by the user and can become a fun to fly anywhere. It is based on the Draco series of racing drones that had already received several awards. According to the company, OOri is optimized in several areas including “speed, agility, technology, design, and build quality.”
OOri has a controller that comes with a 2.5 inch screen. It has vision positioning system. It is easy as it can be used right after unboxing. It is also considered as the fastest micro drone that comes with agility. It can reach to the speed of up to 50 mph, and can reach an altitude of 500 ft. The drone has three flight modes, including beginner mode (in which the user can only pick and fly), intermediate mode (in which the user can show off some flying skills), and racer mode (in which the user can switch to the racing mode). The drone also has assignable LEDs.
The package of OOri consists of the following components:
- UVify OORI
- OORI Transmitter with FPV Screen
- 1 x 660maH battery with quick charging power
- Prop guards
- 8 x Propellers (4 spare)
- Tool kit
- Spare bolts (For when prop guards are removed)
The dimensions of OOri are 90mm x 90mm x 30mm (without prop guard), and 160mm x 160mm x 30mm (with prop guard), and has the weight of 73gm without battery. So, it is almost palm-sized drone that can be used by flying lovers. However, one of the problems with the drone is that it has maximum hovering time of only 5 minutes. Nevertheless, it could be a fun for the users. If you have one, leave the comments below for other readers and users…
The observed proportion of cannabis-attributable ER visits with edible exposure was about 33 times higher than expected
Following legalization of marijuana, Colorado has seen a steep increase in cannabis-related ER visits. In the timeframe between 2012 and 2016, inhalable cannabis resulted in a higher frequency of cannabis-attributable emergency department (ED) visits, although ED visits for acute psychiatric events and cardiovascular symptoms were more common use of edibles. Findings from an observational study are published in Annals of Internal Medicine.
Increased availability and use of marijuana in Colorado has led to an increase in emergency department visits attributable to the drug. Cannabis is most often purchased in flower form for smoking, but anecdotal evidence suggests that edible cannabis products may more frequently contribute to ED visits and may be more toxic than inhalable products.
Researchers from the University of Colorado School of Medicine reviewed health records for 9,973 patients presenting to the UCHealth University of Colorado Hospital ED from 2012 to 2016 to describe and compare visits related to edible and inhaled cannabis exposure. The researchers found a more than 3-fold increase in cannabis-associated ED visits over the time period, with visits due to edible exposure much higher than expected. Specifically, their analysis showed that, although 10.7 percent of ED visits were attributable to edible cannabis, only 0.32 percent of total cannabis sales (in kilograms of tetrahydrocannabinol [THC]) were for edible products. Therefore, compared to inhaled cannabis, the observed proportion of cannabis-attributable ED visits with edible exposure was about 33 times higher than expected. The authors also noted that psychiatric ED visits were more common following edible exposure than inhaled cannabis products.
The authors of an accompanying editorial from the National Institute on Drug Abuse, National Institutes of Health say that this research has important clinical and public health implications. They point out that the slow rate of absorption of orally ingested THC compared with inhalable THC makes it harder for users of edible cannabis to titrate the doses required to achieve the desired drug effects. In addition, the wide variety of innocuous looking edible preparations can lead to overconsumption. This can be compounded by inaccurate labeling of cannabinoid content in edible products. They suggest that future research into the effects of cannabis should focus on THC and CBD content, route of administration, doses consumed, sex, age, body mass index, and the medical conditions for which cannabis might be prescribed. They also suggest greater oversight of manufacturing practices, labeling standards, and quality control of cannabis products marketed to the public.
Media contact: For an embargoed PDF, please contact Lauren Evans at firstname.lastname@example.org. To interview the senior clinical author, Andrew A. Monte, MD, PhD, please contact Jessica Berry at Jessica.Berry@uchealth.org. To reach the authors of the editorial, please contact the NIDA press office at email@example.com or 301-443-6245.